# Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.

> **NCT00421369** · NA · COMPLETED · sponsor: **Hadassah Medical Organization** · enrollment: 35 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** sertraline
- **DRUG:** triiodothyronine (T3)
- **DRUG:** reboxetine

## Key facts

- **NCT ID:** NCT00421369
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** —
- **Final completion:** 2011-08
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00421369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00421369, "Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00421369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*